01Available sources
The milestone
In May 2017, the FDA grants accelerated approval to pembrolizumab for MSI-H or dMMR solid tumors under defined conditions.
Sources for this section
- FDA Approves Pembrolizumab for Tumors with Specific Genetic FeaturesNational Cancer Institute / NIH
LIMITATIONS AND CONTEXT
The scope of this reading
- A historical record limited to the cited event; it does not represent a current care recommendation.
- Discovery, clinical assessment, regulatory approval and access in practice are different stages.
- The 2017 approval had specific eligibility criteria. Consult the source and current regulations for up-to-date information.
ORIGINAL READING
References and sources
- FDA Approves Pembrolizumab for Tumors with Specific Genetic FeaturesNational Cancer Institute / NIHSource publication: 2017-06-20
- National Cancer Institute